Cyclic amine derivatives as EP
There is described a group of novel cyclic amine derivative compounds having an EP 4 receptor agonistic activity. Specifically, the compounds according to the invention are provided with analgesic, antinflammatory, antiglaucoma activity, and also with anti-osteoporosis and antiulcerative activity. The present invention therefore relates to novel cyclic amine derivative compounds, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as pain, glaucoma, ulcerative colitis and osteoporosis.
1. A cyclic amine derivative of Formula (I)
or a pharmaceutically acceptable salt or derivative thereof, wherein:
R 1 and R 2 are independently hydrogen, linear or branched C 1-3 alkyl or joined together they form a cyclopropyl ring;
n is 1 or 2,
R 3 is hydrogen or a linear or branched C 1-3 alkyl,
R 4 is hydrogen, fluorine, or hydroxy group,
R 5 is halogen, cyano, linear or branched C 1-3 alkyl, trifluoromethyl or trifluoromethoxy,
R 6 is hydrogen or halogen.
2. A cyclic amine derivative of Formula (I) according to claim 1 , wherein the halogen in R 5 is fluorine.
3. A cyclic amine derivative of Formula (I) according to claim 1 , wherein the linear or branched C 1-3 alkyl is methyl.
4. A cyclic amine derivative of Formula (I) according to claim 1 , wherein n is 1.
5. A cyclic amine derivative of Formula (I) according to claim 4 , wherein
R 1 is hydrogen,
R 2 is methyl,
R 3 is hydrogen,
R 4 is hydrogen, fluorine or hydroxy,
R 5 is fluorine, trifluoromethyl or methyl,
R 6 is hydrogen.
6. A cyclic amine derivative of Formula (I) according to claim 5 , wherein R 4 is hydrogen.
7. A cyclic amine derivative of Formula (I) according to claim 1 , wherein n is 2.
8. A cyclic amine derivative of Formula (I) according to claim 7 , wherein
R 1 is hydrogen,
R 2 is methyl,
R 3 is hydrogen,
R 4 is hydrogen,
R 5 is fluorine, trifluoromethyl, methyl or trifluoromethoxy,
R 6 is hydrogen.
9. A cyclic amine derivative of Formula (I) according to claim 1 selected from the group consisting of: lithium 4-((S)-1-((R)-1-(3-(trifluoromethyl)benzyl)piperidine-2-carboxamido)ethyl) benzoate, lithium (R)-4-(1-(1-(3-(trifluoromethyl)benzyl) piperidine-2-carboxamido) cyclopropyl) benzoate, (R)-4-(1-(1-(4-fluoro-3-methylbenzyl)piperidine-2-carboxamido)cyclopropyl) benzoic acid, lithium (R)-4-(1-(1-(4-fluoro-3-(trifluoromethyl)benzyl)piperidine-2-carboxamido) cyclopropyl)benzoate, lithium 4-((S)-1-((R)-1-(3-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamido) ethyl)benzoate; and lithium 4-((S)-1-((2R,4R)-4-hydroxy-1-(3-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamido)ethyl) benzoate.
10. A pharmaceutical composition comprising a compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and/or excipient.
11. A method of treatment of a disease selected from the group consisting of: pain, inflammation, glaucoma, osteoporosis and ulcerative colitis, comprising the administration of an effective amount of a compound of Formula (I) according to claim 1 .